ソース:[1] Guardant reports clinical readout update for Shield algorithm (https://www.medicaldevice-network.com/news/gu ...)[2] Guardant Health stock falls 8% despite Evercore ISI's positive outlook - Investing.com (https://vertexaisearch.cloud.google.com/groun ...)[3] Guardant Health's Shield blood test shows 84% sensitivity for colorectal cancer By Investing.com (https://www.investing.com/news/stock-market-n ...)